Literature DB >> 22562653

Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells.

Linda Vignozzi1, Ilaria Cellai, Raffaella Santi, Letizia Lombardelli, Annamaria Morelli, Paolo Comeglio, Sandra Filippi, Federica Logiodice, Marco Carini, Gabriella Nesi, Mauro Gacci, Marie-Pierre Piccinni, Luciano Adorini, Mario Maggi.   

Abstract

Progression of benign prostatic hyperplasia (BPH) involves chronic inflammation and immune dysregulation. Preclinical studies have demonstrated that prostate inflammation and tissue remodeling are exacerbated by hypogonadism and prevented by testosterone supplementation. We now investigated whether, in humans, hypogonadism was associated with more severe BPH inflammation and the in vitro effect of the selective androgen receptor agonist dihydrotestosterone (DHT) on cultures of stromal cells derived from BPH patients (hBPH). Histological analysis of inflammatory infiltrates in prostatectomy specimens from a cohort of BPH patients and correlation with serum testosterone level was performed. Even after adjusting for confounding factors, hypogonadism was associated with a fivefold increased risk of intraprostatic inflammation, which was also more severe than that observed in eugonadal BPH patients. Triggering hBPH cells by inflammatory stimuli (tumor necrosis factor α, lipopolysaccharide, or CD4(+)T cells) induced abundant secretion of inflammatory/growth factors (interleukin 6 (IL6), IL8, and basic fibroblast growth factor (bFGF)). Co-culture of CD4(+)T cells with hBPH cells induced secretion of Th1 inducer (IL12), Th1-recruiting chemokine (interferon γ inducible protein 10, IP10), and Th2 (IL9)- and Th17 (IL17)-specific cytokines. Pretreatment with DHT inhibited NF-κB activation and suppressed secretion of several inflammatory/growth factors, with the most pronounced effects on IL8, IL6, and bFGF. Reduced inflammatory cytokine production by T-cells, an increase in IL10, and a significant reduction of T cells proliferation suggested that DHT exerted a broad anti inflammatory effect on testosterone cells [corrected]. In conclusion, our data demonstrate that DHT exerts an immune regulatory role on human prostatic stromal cells, inhibiting their potential to actively induce and/or sustain autoimmune and inflammatory responses.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22562653     DOI: 10.1530/JOE-12-0142

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  51 in total

Review 1.  Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications.

Authors:  Zachary J Solomon; Jorge Rivera Mirabal; Daniel J Mazur; Taylor P Kohn; Larry I Lipshultz; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2018-11-30

2.  Association between endogenous sex steroid hormones and inflammatory biomarkers in US men.

Authors:  K K Tsilidis; S Rohrmann; K A McGlynn; S J Nyante; D S Lopez; G Bradwin; M Feinleib; C E Joshu; N Kanarek; W G Nelson; E Selvin; E A Platz
Journal:  Andrology       Date:  2013-09-30       Impact factor: 3.842

Review 3.  Benign prostatic hyperplasia: a new metabolic disease?

Authors:  L Vignozzi; G Rastrelli; G Corona; M Gacci; G Forti; M Maggi
Journal:  J Endocrinol Invest       Date:  2014-01-24       Impact factor: 4.256

4.  5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia.

Authors:  C-H Chou; C-L Lin; M-C Lin; F-C Sung; C-H Kao
Journal:  J Endocrinol Invest       Date:  2015-03-17       Impact factor: 4.256

5.  Lessons learned about prostatic transformation from the age-related methylation of 5α-reductase type 2 gene.

Authors:  John T Isaacs
Journal:  Am J Pathol       Date:  2015-02-17       Impact factor: 4.307

Review 6.  Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome.

Authors:  Linda Vignozzi; Mauro Gacci; Mario Maggi
Journal:  Nat Rev Urol       Date:  2016-01-12       Impact factor: 14.432

7.  Upregulation of androgen-responsive genes and transforming growth factor-β1 cascade genes in a rat model of non-bacterial prostatic inflammation.

Authors:  Yasuhito Funahashi; Katherine J O'Malley; Naoki Kawamorita; Pradeep Tyagi; Donald B DeFranco; Ryosuke Takahashi; Momokazu Gotoh; Zhou Wang; Naoki Yoshimura
Journal:  Prostate       Date:  2013-12-17       Impact factor: 4.104

8.  Heme oxygenase levels and metaflammation in benign prostatic hyperplasia patients.

Authors:  Giorgio Ivan Russo; Luca Vanella; Tommaso Castelli; Sebastiano Cimino; Giulio Reale; Daniele Urzì; Giovanni Li Volti; Mauro Gacci; Marco Carini; Fabio Motta; Rosario Caltabiano; Lidia Puzzo; Valeria Sorrenti; Giuseppe Morgia
Journal:  World J Urol       Date:  2015-11-30       Impact factor: 4.226

Review 9.  Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: What Is the Role and Significance of Inflammation?

Authors:  Granville L Lloyd; Jeffrey M Marks; William A Ricke
Journal:  Curr Urol Rep       Date:  2019-08-03       Impact factor: 3.092

10.  Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer.

Authors:  Kouji Izumi; Lei Li; Chawnshang Chang
Journal:  Clin Investig (Lond)       Date:  2014-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.